Mankind Pharma Limited

Mankind Pharma Limited

Mankind Pharma Limited has informed the Exchange regarding the allotment of 49,112 shares under the Mankind Employee Stock Option Plan 2022 to eligible employees.

Mankind Pharma Limited

Mankind Pharma Limited has completed the sale of its 100% stake in Broadway Hospitality Services Private Limited to AKRK Projects LLP and its Partners, effective August 31, 2026.

Mankind Pharma Limited

Mankind Pharma Limited has informed the Exchange regarding the cessation of Mr. Bharat Anand as a Non-Executive Independent Director of the company, effective August 30, 2026.

Mankind Pharma Limited

Mankind Pharma Limited has announced the integration of its wholly owned subsidiary Bharat Serums and Vaccines Limited (BSVL) into the company through voluntary liquidation. The business of BSVL will be distributed to Mankind Pharma on a going concern basis, and Appian, a wholly owned subsidiary of Mankind Pharma, will receive cash proportionate to its shareholding in BSVL.

Mankind Pharma Limited

Mankind Pharma Limited has announced the outcome of its Board Meeting, where it has consented to the integration of Bharat Serums and Vaccines Limited, a wholly owned material subsidiary, into the Company by way of voluntary liquidation. The business of BSVL will be distributed to the Company on a going concern basis, and Appian, a wholly owned subsidiary of the Company, will receive cash proportionate to its shareholding.

Mankind Pharma Limited

Mankind Pharma Limited has informed the Exchange about General Updates, specifically an improvement in Environmental, Social and Governance (ESG) Rating from 57 to 64, classified under the 'Strong' category, and an improvement in Core ESG Rating from 60 to 71.

Mankind Pharma Limited

Mankind Pharma Limited has entered into an exclusive in-licensing agreement with Chongqing Chenan Biopharmaceutical Co., Ltd., China, for the commercialization of two insulin analogues, Insulin Degludec and Insulin Degludec + Aspart Combination, in India. This partnership further strengthens Mankind Pharma's presence in the diabetes segment and expands its portfolio of advanced injectable therapies.

Mankind Pharma Limited

Mankind Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding the dispatch of the Notice of Postal Ballot and providing other requisite information pursuant to the provisions of Sections 108 and 110 of the Companies Act, 2013.

Mankind Pharma Limited

Mankind Pharma Limited has informed the Exchange regarding Notice of Postal Ballot for appointment of Mr. Anish Vanraj Bafna as a Non-Executive Independent Director of the Company.

Mankind Pharma Limited

Mankind Pharma Limited has completed the realignment of security cover for its non-convertible debentures, resulting in the release of pledged shares of Bharat Serums and Vaccines Limited. The revised security cover is 1.26 times the outstanding NCDs as on date.

Mankind Pharma Limited

Mankind Pharma Limited has informed the Exchange about the incorporation of a wholly owned subsidiary company in Netherlands, Mankind Pharma (Netherlands) B.V., as per the Listing Regulations.

Mankind Pharma Limited

Mankind Pharma Limited has informed the Exchange regarding the appointment of Mr. Anish Vanraj Bafna as a Non-Executive Independent Director of the company, effective from August 10, 2026.

Mankind Pharma Limited

Mankind Pharma Limited has informed the Exchange regarding the outcome of its Board Meeting held on August 10, 2026, where the Board appointed Mr. Anish Vanraj Bafna as an Additional Director, designated as a Non-Executive Independent Director, subject to approval of the members of the Company.

Mankind Pharma Limited

Mankind Pharma Limited has informed the Exchange about its participation in upcoming investor conferences, including Emkay Confluence, Equirus Annual India Conference, and Motilal Oswal 22nd Annual Global One-on-One Investor Conference.

Mankind Pharma Limited

Mankind Pharma Limited has submitted the Exchange a copy of the Scrutinizer's report of the 35th Annual General Meeting held on August 04, 2026, and informed the Exchange regarding voting results.

Mankind Pharma Limited

Mankind Pharma Limited held its 35th Annual General Meeting on August 4, 2026, through video conferencing, with 143 members in attendance. The meeting was presided over by Executive Chairman Ramesh Juneja, and the company's financials for the year 2025-26 were discussed.

Mankind Pharma Limited

Mankind Pharma Limited's Q1 FY27 earnings conference call transcript is available on their website, with key highlights including a 13% year-on-year revenue growth to INR4,031 crores, EBITDA of INR1,060 crores, and an EBITDA margin improvement of 250 bps to 26.3%. The company also reported a 12.7% growth in secondary sales as per IQVIA, driven by healthy volume growth of 4.7% and strong momentum in chronic and BSV specialty business.

Mankind Pharma Limited

Mankind Pharma Limited has informed the Exchange about a copy of newspaper publication regarding unaudited financial results for the quarter ended June 30, 2026.

Mankind Pharma Limited

Mankind Pharma Limited has made available the audio recording of its Q1FY27 investor conference call on its website.

Mankind Pharma Limited

Mankind Pharma Limited has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with the company's board of directors approving the issuance of a corporate guarantee in favor of Bharat Serums and Vaccines Limited, a wholly-owned subsidiary. The company has also submitted a certificate from its joint statutory auditors under Regulation 54 of the SEBI (LODR) Regulations, 2015.